Zimmer Biomet Holdings (FRA:ZIM) Research & Development: €388 Mil (TTM As of Mar. 2026)


FRA:ZIM Zimmer Biomet Holdings Inc FRA:ZIM
76 GF Score
Price €76.80
GF Value €106.93
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Zimmer Biomet Holdings Research & Development?

Zimmer Biomet Holdings FRA:ZIM +1.29% 76 Research & Development is €388 Mil as of Mar. 2026. GuruFocus rates FRA:ZIM with a GF Score™ of 76/100 and a GF Value™ of €106.93 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Zimmer Biomet Holdings's Research & Development for the three months ended in Mar. 2026 was €89 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was €388 Mil.

Zimmer Biomet Holdings  (FRA:ZIM) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Zimmer Biomet Holdings Research & Development Related Terms

Zimmer Biomet Holdings Research & Development Historical Data

* Premium members only.

The historical data trend for Zimmer Biomet Holdings's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zimmer Biomet Holdings Research & Development Chart

Zimmer Biomet Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 385.68 383.26 420.63 417.72 391.56

Zimmer Biomet Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 102.31 98.23 98.75 101.37 89.44
FRA:ZIM
76GF Score
Zimmer Biomet Holdings Inc FRA:ZIM
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zimmer Biomet Holdings Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €388 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €388 Mil mean?
Zimmer Biomet Holdings (FRA:ZIM) has a Research & Development of €388 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Zimmer Biomet Holdings and its competitors.
Is Zimmer Biomet Holdings' Research & Development too high?
Zimmer Biomet Holdings' current Research & Development is €388 Mil. Overall, Zimmer Biomet Holdings has a GF Score™ of 76/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zimmer Biomet Holdings' Research & Development compare to PEN and GMED?
Zimmer Biomet Holdings' Research & Development of €388 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Zimmer Biomet Holdings and its competitors. Zimmer Biomet Holdings's current Research & Development is €388 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zimmer Biomet Holdings stock overvalued right now?
Based on GuruFocus' analysis, Zimmer Biomet Holdings (FRA:ZIM) is currently considered Modestly Undervalued. The stock's GF Value™ is €106.93, compared to a current price of €76.80 — trading 28.2% below its estimated fair value. The current Research & Development is €388 Mil. Zimmer Biomet Holdings' overall GF Score™ is 76/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Zimmer Biomet Holdings (FRA:ZIM), the current Research & Development is €388 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zimmer Biomet Holdings (FRA:ZIM) Overvalued in 2026?

Based on GuruFocus' analysis, Zimmer Biomet Holdings stock appears to be undervalued. The current stock price of €76.80 is trading 28.2% below its estimated GF Value™ of €106.93. GuruFocus considers Zimmer Biomet Holdings to be Modestly Undervalued.

Key valuation signals for FRA:ZIM:

  • Research & Development: €388 Mil
  • GF Value™: €106.93 vs. price of €76.80 (28.2% below fair value)
  • GF Score™: 76/100 with 3 warning signs

No single metric tells the full story. See the FRA:ZIM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zimmer Biomet Holdings Business Description

Address 345 East Main Street, Warsaw, IN, USA, 46580
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
76GF Score

Get the complete analysis for FRA:ZIM

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€76.80
Price
€106.93
GF Value